Evidence map›Paper›PMID 34726095›Full record

ArticleAnnals of medicine2021

Harm reduction for the treatment of patients with severe injection-related infections: description of the Jackson SIRI Team.

David P Serota, Hansel E Tookes, Belén Hervera, Babley M Gayle, Cara R Roeck, Edward Suarez, David W Forrest, Michael A Kolber, Tyler S Bartholomew, Allan E Rodriguez and 1 more

Open access · goldAbstract read
In one paragraph

Article in Annals of medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Long-term Risk of Serious Infections and Mortality Among Patients Surviving Drug Use-Associated Infective Endocarditis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Frame Shift: Focusing on Harm Reduction and Shared Decision Making for People Who Use Drugs Hospitalized With Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

David P SerotaDivision of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Hansel E TookesDivision of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Belén HerveraDivision of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Babley M GayleJackson Memorial Hospital, Jackson Health System, Miami, FL, USA.
Cara R RoeckJackson Memorial Hospital, Jackson Health System, Miami, FL, USA.
Edward SuarezDivision of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
David W ForrestDepartment of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.
Michael A KolberDivision of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Tyler S BartholomewDepartment of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID 0000-0002-9384-0812
Allan E RodriguezDivision of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Susanne Doblecki-LewisDivision of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
University of Miami · USJackson Memorial Hospital · US

Funding

A Multi-site Multi-Setting RCT of Integrated HIV Prevention and HCV Care for PWIDR01DA045713 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BRUNEAU, JULIE, FEASTER, DANIEL J · 2017 to 2022
$8.2M
Training Program on HIV and Substance Use in the Criminal Justice SystemT32DA037801 · NIDA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Nabila El-Bassel, Lisa R Metsch · 2014 to 2026
$5.7M
NIDA NIH HHS R01 DA045713NIDA NIH HHS T32 DA037801
6 · The paper itself

Abstract

introductionHospitalizations for severe injection-related infections (SIRI), such as endocarditis, osteomyelitis, and skin and soft tissue infections (SSTI) are increasingly common. People who inject drugs (PWID) experiencing SIRIs often receive inadequate substance use disorder (SUD) treatment and lack of access to harm reduction services. This translates into lengthy hospitalizations with high rates of patient-directed discharge, readmissions, and post-hospitalization mortality. The purpose of this study was to describe the development of an integrated "SIRI Team" and its initial barriers and facilitators to success. MATERIALS AND

methodsThe Jackson SIRI Team was developed to improve both hospital and patient-level outcomes for individuals hospitalized with SIRIs at Jackson Memorial Hospital, a 1550-bed public hospital in Miami, Florida, United States. The SIRI Team provides integrated infectious disease and SUD treatment across the healthcare system starting from the inpatient setting and continuing for 90-days post-hospital discharge. The team uses a harm reduction approach, provides care coordination, focuses on access to medications for opioid use disorder (MOUD), and utilizes a variety of infection and addiction treatment modalities to suit each individual patient.

resultsOver the initial 8-months of the SIRI Team, 21 patients were treated with 20 surviving until discharge. Infections included osteomyelitis, endocarditis, bacteraemia/fungemia, SSTIs, and septic arthritis. All patients had OUD and 95% used stimulants. All patients were discharged on MOUD and 95% completed their prescribed antibiotic course. At 90-days post-discharge, 25% had been readmitted and 70% reported taking MOUD.

conclusionsA model of integrated infectious disease and SUD care for the treatment of SIRIs has the potential to improve infection and addiction outcomes. Providing attentive, patient-centered care, using a harm reduction approach can facilitate engagement of this marginalized population with the healthcare system.KEY MESSAGESIntegrated infectious disease and addiction treatment is a novel approach to treating severe injection-related infections.Harm reduction should be applied to treating patients with severe injection-related infections with a goal of facilitating antibiotic completion, remission from substance use disorder, and reducing hospital readmissions.

Indexed as

Harm ReductionSyringesAdultAftercareAnti-Bacterial AgentsEndocarditisFemaleHumansInjection Site ReactionMaleOpioid-Related DisordersOsteomyelitisPatient DischargeSoft Tissue InfectionsSubstance Abuse, IntravenousUnited StatesAnti-Bacterial AgentsEndocarditisopioid use disorderskin and soft tissue infectionsubstance use disorder

Identifiers

PMID34726095
PMCPMC8567885
OpenAlexW3211084813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.